BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22438050)

  • 21. Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer.
    Marchand V; Angelergues A; Gobaux V; Hajage D; Kirova YM; Campana F; Dendale R; Reyal F; Pierga JY; Fourquet A; Bollet MA
    Am J Clin Oncol; 2013 Oct; 36(5):425-9. PubMed ID: 22706171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
    Parton M; Krajewski S; Smith I; Krajewska M; Archer C; Naito M; Ahern R; Reed J; Dowsett M
    Clin Cancer Res; 2002 Jul; 8(7):2100-8. PubMed ID: 12114409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
    Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
    Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
    Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma.
    Tsimafeyeu I; Demidov L; Stepanova E; Wynn N; Ta H
    Scand J Urol Nephrol; 2011 Apr; 45(3):190-5. PubMed ID: 21329481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
    Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
    Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
    Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
    Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases.
    Neri A; Megha T; Bettarini F; Tacchini D; Mastrogiulio MG; Marrelli D; Pinto E; Tosi P
    Hum Pathol; 2012 Aug; 43(8):1184-91. PubMed ID: 22397869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS.
    Zhang K; Yuan K; Wu H; Li Q; Wang Y; Chen S; Zhang L; Gu H; Fu R
    Appl Biochem Biotechnol; 2012 Feb; 166(3):753-63. PubMed ID: 22127810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
    Grönberg M; Fjällskog ML; Jirström K; Janson ET
    Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.